Vaxart (VXRT) reshapes board committees, names new chairs
Rhea-AI Filing Summary
Vaxart, Inc., a Delaware corporation whose common stock is quoted on the OTCQX Best Market under the symbol VXRT, reported changes to the structure of its Board committees.
On July 27, 2026, the Board approved a reorganization of the Nominating and Governance Committee and the Compensation Committee, effective August 1, 2026. Kevin P. Finney was appointed chair of the Nominating and Governance Committee, which will also include David Wheadon, M.D. The Compensation Committee will be chaired by James B. Breitmeyer, M.D., Ph.D., with Elaine J. Heron, Ph.D. and W. Mark Watson serving as members.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Committee reorganization approval date: July 27, 2026
Committee changes effective date: August 1, 2026
Trading symbol: VXRT
3 metrics
Committee reorganization approval date
July 27, 2026
Date the Board approved changes to the Nominating and Governance and Compensation Committees
Committee changes effective date
August 1, 2026
Effective date for new committee chairs and memberships
Trading symbol
VXRT
Symbol for Vaxart common stock quoted on the OTCQX Best Market
Key Terms
Nominating and Governance Committee, Compensation Committee, Emerging Growth Company, OTCQX® Best Market
4 terms
Nominating and Governance Committee regulatory
"approved the reorganization of its Nominating and Governance Committee and the Compensation Committee"
A nominating and governance committee is a group of board members tasked with choosing and evaluating directors, planning leadership succession, and setting the company’s board-related rules and ethical standards. Think of it as the company’s hiring and rule-making panel for its top overseers. Its work matters to investors because it shapes who governs the company, how leadership transitions are handled, and whether the board can effectively oversee management and protect shareholder interests.
Compensation Committee regulatory
"reorganization of its Nominating and Governance Committee and the Compensation Committee, and the appointments"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
Emerging Growth Company regulatory
"Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
OTCQX® Best Market market
"The registrant’s common stock is quoted on the OTCQX® Best Market under the symbol “VXRT.”"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What board governance changes did Vaxart (VXRT) report on July 27, 2026?
Vaxart reported a reorganization of its Nominating and Governance Committee and Compensation Committee. The Board approved new chairs and memberships for these committees, reshaping oversight roles for director nominations, governance matters, and executive compensation policies.
When do Vaxart (VXRT) board committee changes become effective?
The board committee changes at Vaxart become effective on August 1, 2026. On that date, the newly appointed chairs and members of the Nominating and Governance Committee and Compensation Committee formally assume their updated responsibilities.
Who is the new chair of Vaxart (VXRT) Nominating and Governance Committee?
The new chair of Vaxart’s Nominating and Governance Committee is Kevin P. Finney. He will lead this committee, which also includes member David Wheadon, M.D., following the reorganization effective August 1, 2026.
Who leads Vaxart (VXRT) Compensation Committee and who serves on it?
The Compensation Committee is chaired by James B. Breitmeyer, M.D., Ph.D. Other members are Elaine J. Heron, Ph.D. and W. Mark Watson, with this composition effective August 1, 2026.
On which market is Vaxart (VXRT) common stock quoted and under what symbol?
Vaxart’s common stock is quoted on the OTCQX Best Market under the symbol VXRT. This marketplace provides electronic quotation and trading for U.S. over-the-counter securities.
Which board committee recommended the Vaxart (VXRT) committee reorganization?
The Nominating and Governance Committee recommended the reorganization of Vaxart’s Nominating and Governance and Compensation Committees. The Board approved these changes on July 27, 2026, with effectiveness on August 1, 2026.